{"id":56201,"date":"2021-12-14T05:26:27","date_gmt":"2021-12-14T05:26:27","guid":{"rendered":"https:\/\/pr.asianetpakistan.com\/?p=84091"},"modified":"2021-12-14T05:26:27","modified_gmt":"2021-12-14T05:26:27","slug":"i-mab-biopharma-and-agc-biologics-partner-on-late-phase-project","status":"publish","type":"post","link":"https:\/\/indonesiatribune.com\/i-mab-biopharma-and-agc-biologics-partner-on-late-phase-project\/","title":{"rendered":"I-MAB Biopharma and AGC Biologics Partner on Late-Phase Project"},"content":{"rendered":"
\n

Global CDMO utilizes Seattle facility\u2019s mammalian biologics expertise to support late-stage clinical trials for leading international biopharma organization<\/h4>\n

Seattle, Dec. 13, 2021 (GLOBE NEWSWIRE) — AGC Biologics<\/a>, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), today announced a new partnership with I-MAB Biopharma (Nasdaq: IMAB). The I-MAB treatment being developed is approaching late-phase clinical trials and AGC Biologics will manufacture the materials at its site in Seattle<\/a>, while also supporting the launch readiness of I-MAB\u2019s product.<\/p>\n

AGC Biologics operates multiple mammalian cGMP manufacturing lines and a variety of scales at its Seattle cell culture facility. The site is designed for capacity and technological flexibility, and has an extensive variety of single-use and stainless steel systems that meet the latest guidelines required for cGMP compliance. The Seattle site also has a long history of successful inspections by the FDA and the site is approved for commercial production. All of these features and capabilities combined make the AGC Biologics Seattle facility an ideal location to support I-MAB\u2019s goals and bring this treatment through its next clinical phase.<\/p>\n

\u201cWe look forward to partnering with a true pioneer in innovative clinical research and development, and working together to help bring I-MAB’s product through the final clinical stages and to commercialization,\u201d said Jean-Baptiste Agnus, Chief Business Officer of AGC Biologics. \u201cOur team in Seattle is an ideal customer-focused group of scientists to help I-MAB in its promising journey for this treatment.\u201d<\/p>\n

AGC Biologics\u2019 Seattle facility has capabilities for developing a wide range of mammalian and microbial programs, and has delivered several approved commercial products.<\/p>\n

To learn more about the biologics capabilities AGC Biologics offers across its network of seven global facilities visit www.agcbio.com\/capabilities<\/a>.<\/p>\n

About AGC Biologics<\/strong>
\nAGC Biologics is a leading global biopharmaceutical Contract Development and Manufacturing Organization (CDMO) with a strong commitment to delivering the highest standard of service as we work side-by-side with our clients and partners, every step of the way. We provide world-class development and manufacture of mammalian and microbial-based therapeutic proteins, plasmid DNA (pDNA), viral vectors, and genetically engineered cells. Our global network spans the U.S., Europe, and Asia, with cGMP-compliant facilities in Seattle, Washington; Boulder and Longmont, Colorado; Copenhagen, Denmark; Heidelberg, Germany; Milan, Italy; and Chiba, Japan and we currently employ more than 2,000 employees worldwide. Our commitment to continuous innovation fosters the technical creativity to solve our clients\u2019 most complex challenges, including specialization in fast-track projects and rare diseases. AGC Biologics is the partner of choice. To learn more, visit www.agcbio.com<\/a>.<\/p>\n

Nick McDonald\r\nAGC Biologics\r\n(425) 419-3555\r\nnmcdonald@agc.com<\/a>\r\n<\/pre>\n<\/div>\n","protected":false},"excerpt":{"rendered":"
Global CDMO utilizes Seattle facility\u2019s mammalian biologics expertise to support late-stage clinical trials for leading international biopharma organization Seattle, Dec. 13, 2021 (GLOBE NEWSWIRE) \u2014 AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), today announced a new partnership with I-MAB Biopharma (Nasdaq: IMAB). The I-MAB treatment being developed is approaching late-phase [\u2026]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"yoast_head":"\nI-MAB Biopharma and AGC Biologics Partner on Late-Phase Project - Indonesia Tribune<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/indonesiatribune.com\/i-mab-biopharma-and-agc-biologics-partner-on-late-phase-project\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"I-MAB Biopharma and AGC Biologics Partner on Late-Phase Project - Indonesia Tribune\" \/>\n<meta property=\"og:description\" content=\"Global CDMO utilizes Seattle facility\u2019s mammalian biologics expertise to support late-stage clinical trials for leading international biopharma organization Seattle, Dec. 13, 2021 (GLOBE NEWSWIRE) \u2014 AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), today announced a new partnership with I-MAB Biopharma (Nasdaq: IMAB). The I-MAB treatment being developed is approaching late-phase [\u2026]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/indonesiatribune.com\/i-mab-biopharma-and-agc-biologics-partner-on-late-phase-project\/\" \/>\n<meta property=\"og:site_name\" content=\"Indonesia Tribune\" \/>\n<meta property=\"article:published_time\" content=\"2021-12-14T05:26:27+00:00\" \/>\n<meta name=\"author\" content=\"admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/indonesiatribune.com\/i-mab-biopharma-and-agc-biologics-partner-on-late-phase-project\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/indonesiatribune.com\/i-mab-biopharma-and-agc-biologics-partner-on-late-phase-project\/\"},\"author\":{\"name\":\"admin\",\"@id\":\"https:\/\/indonesiatribune.com\/#\/schema\/person\/7aed831417039bb12c28cffff4aa4192\"},\"headline\":\"I-MAB Biopharma and AGC Biologics Partner on Late-Phase Project\",\"datePublished\":\"2021-12-14T05:26:27+00:00\",\"dateModified\":\"2021-12-14T05:26:27+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/indonesiatribune.com\/i-mab-biopharma-and-agc-biologics-partner-on-late-phase-project\/\"},\"wordCount\":430,\"publisher\":{\"@id\":\"https:\/\/indonesiatribune.com\/#organization\"},\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/indonesiatribune.com\/i-mab-biopharma-and-agc-biologics-partner-on-late-phase-project\/\",\"url\":\"https:\/\/indonesiatribune.com\/i-mab-biopharma-and-agc-biologics-partner-on-late-phase-project\/\",\"name\":\"I-MAB Biopharma and AGC Biologics Partner on Late-Phase Project - Indonesia Tribune\",\"isPartOf\":{\"@id\":\"https:\/\/indonesiatribune.com\/#website\"},\"datePublished\":\"2021-12-14T05:26:27+00:00\",\"dateModified\":\"2021-12-14T05:26:27+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/indonesiatribune.com\/i-mab-biopharma-and-agc-biologics-partner-on-late-phase-project\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/indonesiatribune.com\/i-mab-biopharma-and-agc-biologics-partner-on-late-phase-project\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/indonesiatribune.com\/i-mab-biopharma-and-agc-biologics-partner-on-late-phase-project\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/indonesiatribune.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"I-MAB Biopharma and AGC Biologics Partner on Late-Phase Project\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/indonesiatribune.com\/#website\",\"url\":\"https:\/\/indonesiatribune.com\/\",\"name\":\"Indonesia Tribune\",\"description\":\"New Thinking New News\",\"publisher\":{\"@id\":\"https:\/\/indonesiatribune.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/indonesiatribune.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/indonesiatribune.com\/#organization\",\"name\":\"Indonesia Tribune\",\"url\":\"https:\/\/indonesiatribune.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/indonesiatribune.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/indonesiatribune.com\/wp-content\/uploads\/2023\/05\/Indonesia-Tribune-e1700732543917.png\",\"contentUrl\":\"https:\/\/indonesiatribune.com\/wp-content\/uploads\/2023\/05\/Indonesia-Tribune-e1700732543917.png\",\"width\":365,\"height\":87,\"caption\":\"Indonesia Tribune\"},\"image\":{\"@id\":\"https:\/\/indonesiatribune.com\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/indonesiatribune.com\/#\/schema\/person\/7aed831417039bb12c28cffff4aa4192\",\"name\":\"admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/indonesiatribune.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/ff4aa10d4f36ab9dc3cce9e101792273?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/ff4aa10d4f36ab9dc3cce9e101792273?s=96&d=mm&r=g\",\"caption\":\"admin\"},\"url\":\"https:\/\/indonesiatribune.com\/author\/admin\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"I-MAB Biopharma and AGC Biologics Partner on Late-Phase Project - Indonesia Tribune","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/indonesiatribune.com\/i-mab-biopharma-and-agc-biologics-partner-on-late-phase-project\/","og_locale":"en_US","og_type":"article","og_title":"I-MAB Biopharma and AGC Biologics Partner on Late-Phase Project - Indonesia Tribune","og_description":"Global CDMO utilizes Seattle facility\u2019s mammalian biologics expertise to support late-stage clinical trials for leading international biopharma organization Seattle, Dec. 13, 2021 (GLOBE NEWSWIRE) \u2014 AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), today announced a new partnership with I-MAB Biopharma (Nasdaq: IMAB). The I-MAB treatment being developed is approaching late-phase [\u2026]","og_url":"https:\/\/indonesiatribune.com\/i-mab-biopharma-and-agc-biologics-partner-on-late-phase-project\/","og_site_name":"Indonesia Tribune","article_published_time":"2021-12-14T05:26:27+00:00","author":"admin","twitter_card":"summary_large_image","twitter_misc":{"Written by":"admin","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/indonesiatribune.com\/i-mab-biopharma-and-agc-biologics-partner-on-late-phase-project\/#article","isPartOf":{"@id":"https:\/\/indonesiatribune.com\/i-mab-biopharma-and-agc-biologics-partner-on-late-phase-project\/"},"author":{"name":"admin","@id":"https:\/\/indonesiatribune.com\/#\/schema\/person\/7aed831417039bb12c28cffff4aa4192"},"headline":"I-MAB Biopharma and AGC Biologics Partner on Late-Phase Project","datePublished":"2021-12-14T05:26:27+00:00","dateModified":"2021-12-14T05:26:27+00:00","mainEntityOfPage":{"@id":"https:\/\/indonesiatribune.com\/i-mab-biopharma-and-agc-biologics-partner-on-late-phase-project\/"},"wordCount":430,"publisher":{"@id":"https:\/\/indonesiatribune.com\/#organization"},"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/indonesiatribune.com\/i-mab-biopharma-and-agc-biologics-partner-on-late-phase-project\/","url":"https:\/\/indonesiatribune.com\/i-mab-biopharma-and-agc-biologics-partner-on-late-phase-project\/","name":"I-MAB Biopharma and AGC Biologics Partner on Late-Phase Project - Indonesia Tribune","isPartOf":{"@id":"https:\/\/indonesiatribune.com\/#website"},"datePublished":"2021-12-14T05:26:27+00:00","dateModified":"2021-12-14T05:26:27+00:00","breadcrumb":{"@id":"https:\/\/indonesiatribune.com\/i-mab-biopharma-and-agc-biologics-partner-on-late-phase-project\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/indonesiatribune.com\/i-mab-biopharma-and-agc-biologics-partner-on-late-phase-project\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/indonesiatribune.com\/i-mab-biopharma-and-agc-biologics-partner-on-late-phase-project\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/indonesiatribune.com\/"},{"@type":"ListItem","position":2,"name":"I-MAB Biopharma and AGC Biologics Partner on Late-Phase Project"}]},{"@type":"WebSite","@id":"https:\/\/indonesiatribune.com\/#website","url":"https:\/\/indonesiatribune.com\/","name":"Indonesia Tribune","description":"New Thinking New News","publisher":{"@id":"https:\/\/indonesiatribune.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/indonesiatribune.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/indonesiatribune.com\/#organization","name":"Indonesia Tribune","url":"https:\/\/indonesiatribune.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/indonesiatribune.com\/#\/schema\/logo\/image\/","url":"https:\/\/indonesiatribune.com\/wp-content\/uploads\/2023\/05\/Indonesia-Tribune-e1700732543917.png","contentUrl":"https:\/\/indonesiatribune.com\/wp-content\/uploads\/2023\/05\/Indonesia-Tribune-e1700732543917.png","width":365,"height":87,"caption":"Indonesia Tribune"},"image":{"@id":"https:\/\/indonesiatribune.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/indonesiatribune.com\/#\/schema\/person\/7aed831417039bb12c28cffff4aa4192","name":"admin","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/indonesiatribune.com\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/ff4aa10d4f36ab9dc3cce9e101792273?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/ff4aa10d4f36ab9dc3cce9e101792273?s=96&d=mm&r=g","caption":"admin"},"url":"https:\/\/indonesiatribune.com\/author\/admin\/"}]}},"_links":{"self":[{"href":"https:\/\/indonesiatribune.com\/wp-json\/wp\/v2\/posts\/56201"}],"collection":[{"href":"https:\/\/indonesiatribune.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/indonesiatribune.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/indonesiatribune.com\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/indonesiatribune.com\/wp-json\/wp\/v2\/comments?post=56201"}],"version-history":[{"count":0,"href":"https:\/\/indonesiatribune.com\/wp-json\/wp\/v2\/posts\/56201\/revisions"}],"wp:attachment":[{"href":"https:\/\/indonesiatribune.com\/wp-json\/wp\/v2\/media?parent=56201"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/indonesiatribune.com\/wp-json\/wp\/v2\/categories?post=56201"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/indonesiatribune.com\/wp-json\/wp\/v2\/tags?post=56201"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}